FGFR-3/ CD333/ FGFR3, Human, Recombinant-上海极威生物商城-Elisa试剂盒,白介素ELISA试剂盒,酶联免疫试剂盒,Gibco胎牛血清,Hyclone胎牛血清,胎牛血清等实验耗材一站式采购平台

产品概述

产品信息

别名	Fibroblast Growth Factor Receptor 3; FGFR-3; CD333; FGFR3; JTK4; IIIc
物种	Human
表达宿主	Human Cells
序列信息	Glu23-Gly375
检索号	NP_001156685.1
分子量	39 kDa
表观分子量	60-75 kDa
标签	C-6His
生物活性	Testing in progress

产品特性

纯度	>95% as determined by reducing SDS-PAGE.
内毒素	< 1.0 EU per μg as determined by LAL test.
保存	Lyophilized Protein should be stored at < -20℃, though stable at room temperature for 3 weeks. Reconstituted Protein solution can be stored at 4-7℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
运输	The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.
制剂	Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4.
复融	Please refer to it for detailed information.

背景介绍

Fibroblast Growth Factors (FGFs) comprise a family of at least eighteen structurally related Proteins that are involved in a multitude of physiological and pathological cellular processes, including cell growth, differentiation, angiogenesis, wound healing and tumorgenesis. The biological activities of the FGFs are mediated by a family of type I transmembrane tyrosine kinases which undergo dimerization and autophosphorylation after Ligand binding. Four distinct genes encoding closely related FGF Receptors, FGF R1-4, are known. All four genes for FGF Rs encode Proteins with an N-terminal signal peptide, three immunoglobulin (Ig)-like domains, an acid-box region containing a run of acidic residues between the IgI and IgII domains, a transmembrane domain and the split tyrosine-kinase domain. Multiple forms of FGF R1-3 are generated by alternative splicing of the mRNAs. A frequent splicing event involving FGF R1 and 2 results in Receptors containing all three Ig domains, referred to as the α isoform, or only IgII and IgIII, referred to as the β isoform. Only the α isoform has been identified for FGF R3 and FGF R4. Additional splicing events for FGF R1-3, involving the C-terminal half of the IgIII domain encoded by two mutually exclusive alternative exons, generate FGF Receptors with alternative IgIII domains (IIIb and IIIc). The complex patterns of expression of these Receptors as well as the specificity of their interactions with the various FGF Ligand family members are under investigation.